Abstract
The subthalamic nucleus (STN) is a primary target for deep brain stimulation in Parkinson's disease (PD). Although small in size, the STN is commonly partitioned into sensorimotor, cognitive/associative, and limbic subregions based on its structural connectivity profile to cortical areas. We investigated whether such a regional specialization is also supported by functional connectivity between local field potential recordings and simultaneous magnetoencephalography. Using a novel data set of 21 PD patients, we replicated previously reported cortico-STN coherence networks in the theta/alpha and beta frequency ranges, and looked for the spatial distribution of these networks within the STN region. Although theta/alpha and beta coherence peaks were both observed in on-medication recordings from electrode contacts at several locations within and around the STN, sites with theta/alpha coherence peaks were situated at significantly more inferior MNI coordinates than beta coherence peaks. Sites with only theta/alpha coherence peaks, i.e. without distinct beta coherence, were mostly located near the border of sensorimotor and cognitive/associative subregions as defined by a tractography-based atlas of the STN. Peak coherence values were largely unaltered by the medication state of the subject, however, theta/alpha peaks were more often identified in recordings obtained after administration of dopaminergic medication. Our findings suggest the existence of a frequency-specific topography of cortico-STN coherence within the STN, albeit with considerable spatial overlap between functional networks. Consequently, optimization of deep brain stimulation targeting might remain a trade-off between alleviating motor symptoms and avoiding adverse neuropsychiatric side effects.
Original language | English |
---|---|
Article number | 119320 |
Pages (from-to) | 1-11 |
Number of pages | 11 |
Journal | NeuroImage |
Volume | 257 |
Early online date | 14 May 2022 |
DOIs | |
Publication status | Published - 15 Aug 2022 |
Bibliographical note
Funding Information:This research was supported by the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 795866 (B.C.M.v.W.), W.J.N., A.H., and A.A.K. received funding from the Deutsche Forschungsgemeinschaft (DFG (German Research Foundation) – Project-ID 424778381 – TRR 295; A.H. received also Grant 410169619), D.K. was supported by the BIH-Charité Clinician Scientist Program funded by the Charité - Universitätsmedizin Berlin and the Berlin Institute of Health, A.H. was supported by the National Institutes of Health (2R01 MH113929) as well as the New Venture Fund (FFOR Seed Grant), T.S. relied on the DFG Core Facility ''Metrology of Ultra-Low Magnetic Fields'' grant number KO5321/3 and TR408/11. The Wellcome Centre for Human Neuroimaging is supported by core funding from Wellcome (203147/Z/16/Z). This is an EU Joint Programme - Neurodegenerative Disease (JPND) project. The project is supported through the following funding organisations under the aegis of JPND - www.jpnd.eu (B.C.M.v.W.: the Netherlands Organisation for Health Research and Development (ZonMw) - The Netherlands; A.H.: the Deutsches Zentrum für Luft- und Raumfahrt - Germany).
Funding Information:
This research was supported by the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 795866 (B.C.M.v.W.), W.J.N., A.H., and A.A.K. received funding from the Deutsche Forschungsgemeinschaft (DFG ( German Research Foundation ) – Project- ID 424778381 – TRR 295 ; A.H. received also Grant 410169619 ), D.K. was supported by the BIH-Charité Clinician Scientist Program funded by the Charité - Universitätsmedizin Berlin and the Berlin Institute of Health, A.H. was supported by the National Institutes of Health (2R01 MH113929) as well as the New Venture Fund (FFOR Seed Grant), T.S. relied on the DFG Core Facility ''Metrology of Ultra-Low Magnetic Fields '' grant number KO5321/3 and TR408/11 . The Wellcome Centre for Human Neuroimaging is supported by core funding from Wellcome (203147/Z/16/Z). This is an EU Joint Programme - Neurodegenerative Disease (JPND) project. The project is supported through the following funding organisations under the aegis of JPND - www.jpnd.eu (B.C.M.v.W.: the Netherlands Organisation for Health Research and Development (ZonMw) - The Netherlands; A.H.: the Deutsches Zentrum für Luft- und Raumfahrt - Germany).
Publisher Copyright:
© 2022
Funding
This research was supported by the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 795866 (B.C.M.v.W.), W.J.N., A.H., and A.A.K. received funding from the Deutsche Forschungsgemeinschaft (DFG (German Research Foundation) – Project-ID 424778381 – TRR 295; A.H. received also Grant 410169619), D.K. was supported by the BIH-Charité Clinician Scientist Program funded by the Charité - Universitätsmedizin Berlin and the Berlin Institute of Health, A.H. was supported by the National Institutes of Health (2R01 MH113929) as well as the New Venture Fund (FFOR Seed Grant), T.S. relied on the DFG Core Facility ''Metrology of Ultra-Low Magnetic Fields'' grant number KO5321/3 and TR408/11. The Wellcome Centre for Human Neuroimaging is supported by core funding from Wellcome (203147/Z/16/Z). This is an EU Joint Programme - Neurodegenerative Disease (JPND) project. The project is supported through the following funding organisations under the aegis of JPND - www.jpnd.eu (B.C.M.v.W.: the Netherlands Organisation for Health Research and Development (ZonMw) - The Netherlands; A.H.: the Deutsches Zentrum für Luft- und Raumfahrt - Germany). This research was supported by the European Union's Horizon 2020 research and innovation programme under the Marie Sklodowska-Curie grant agreement No 795866 (B.C.M.v.W.), W.J.N., A.H., and A.A.K. received funding from the Deutsche Forschungsgemeinschaft (DFG ( German Research Foundation ) – Project- ID 424778381 – TRR 295 ; A.H. received also Grant 410169619 ), D.K. was supported by the BIH-Charité Clinician Scientist Program funded by the Charité - Universitätsmedizin Berlin and the Berlin Institute of Health, A.H. was supported by the National Institutes of Health (2R01 MH113929) as well as the New Venture Fund (FFOR Seed Grant), T.S. relied on the DFG Core Facility ''Metrology of Ultra-Low Magnetic Fields '' grant number KO5321/3 and TR408/11 . The Wellcome Centre for Human Neuroimaging is supported by core funding from Wellcome (203147/Z/16/Z). This is an EU Joint Programme - Neurodegenerative Disease (JPND) project. The project is supported through the following funding organisations under the aegis of JPND - www.jpnd.eu (B.C.M.v.W.: the Netherlands Organisation for Health Research and Development (ZonMw) - The Netherlands; A.H.: the Deutsches Zentrum für Luft- und Raumfahrt - Germany).
Funders | Funder number |
---|---|
BIH-Charité | |
Neurodegenerative Disease | |
National Institutes of Health | TR408/11, KO5321/3 |
National Institute of Mental Health | R01MH113929 |
Wellcome Trust | 203147/Z/16/Z |
H2020 Marie Skłodowska-Curie Actions | 795866 |
EU Joint Programme – Neurodegenerative Disease Research | |
Deutsche Forschungsgemeinschaft | 410169619, 424778381 – TRR 295 |
ZonMw | |
Charité – Universitätsmedizin Berlin | |
Deutsches Zentrum für Luft- und Raumfahrt | |
Horizon 2020 | |
Berlin Institute of Health |
Keywords
- Deep brain stimulation
- Functional connectivity
- Magnetoencephalography
- Parkinson's disease
- Subthalamic nucleus